Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin

International Journal of Preventive Medicine

Volumn 4, Issue 8, 2013, Pages 902-910

  Dash, Amitabh ^a   Maiti, Rituparna ^a   Bandakkanavar, Tejaswi Kumar Akantappa ^a   Bhaskar, Amit ^b   Prakash, Jai ^c   Pandey, Bajarang Lal ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic kidney disease; Clopidogrel; Low dose aspirin; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; CREATININE; ELECTROLYTE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UREA;

ADD ON THERAPY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DETERIORATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERNATREMIA; KIDNEY FUNCTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK SCORING; UREA BLOOD LEVEL;

EID: 84884168240     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Modi GK, Jha V. The incidence of end-stage renal disease in India: A population-based study. Kidney Int 2006;70:2131-3.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:S1296-305.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000;35(Suppl 1):S117-31.
4. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up Program (HDFP). The hypertension detection and follow-up Program Cooperative. Group. Hypertension 1989;13(5 Suppl):I80-93.
5. Sarnak M, Levey A, Schoolwerth A, Coresh J. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-9.
6. Berl T, Henrich W. Kidney-heart interactions: Epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006;1:8-18.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
8. The CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
9. The Clopidogrel in Unstable angina to prevent Recurrent Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
10. rd, Fry ET, DeLago A, Wilmer C, et al.; CREDO investigators. Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-20.
11. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005;45:473-84.
12. Deray G, Brouard R, Bagnis C. Safety and activity of clopidogrel, an antiplatelet agent, in chronic renal failure patients. J Am Soc Nephrol 1995;6(Suppl 1):384.
13. Deray G, Bagnis C, Brouard R, Necciari J, Leenhardt AF, Raymond F, et al. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig 1998;16:319-28.
14. Levin A, Stevens L, McCullough PA. Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. Postgrad Med 2002;111:53-60.
15. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. World Health Organisation. Obesity: Prevalence and managing the global epidemic. Report of WHO consultation on obesity. Geneva; 1997.
17. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular Disease in the EPIC Norfolk Cohort. Diabetes Care 2009;32:708-13.
18. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988;318:1657-66.
19. Fujihara CK, De Lourdes Noronha I, Malheiros, Antunes GR, de Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000;11:283-90.
20. Park JS, Kim SB. C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients. Nephrology (Carlton) 2003;8(Suppl): S40-4.
21. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevation of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
22. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
23. Stevens RJ, Kothari V, Adler AI, Stratton IM, Rury R; Holman on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
25. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-84.
26. Rice EK, Tesch GH, Cao Z, Cooper ME, Metz CN, Bucala R, et al. Induction of MIF synthesis and secretion by tubular epithelial cells: A novel action of angiotensin II. Kidney Int 2003;63:1265-75.
27. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-9.
28. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
29. Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16:133-43.
30. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992;41:297-309.
31. Tu X, Chen X, Xie Y, Shi S, Wang J, Chen Y, et al. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J Am Soc Nephrol 2008;19:77-83.